Anti-Aging
Product overview
NAD+ is supplied for cellular signaling, mitochondrial function and stress-response research. The catalog identity is Nadide; order-specific purity, composition and net content are confirmed against the applicable Certificate of Analysis.
Available formats include 100mg × 10 vials, 500mg × 10 vials, 1000mg × 10 vials. CelluPep supports qualified laboratory, biotechnology and distribution inquiries with specification review, batch documentation and coordinated global fulfillment.
For research use only. Not for human consumption, diagnostic use or therapeutic use.
Product identification
Reference identity information supports product evaluation. Batch-specific test results remain subject to the documentation supplied with each order.
Chemical identity
- Product name
- NAD+
- CAS number
- 53-84-9
- Molecular formula
- C21H27N7O14P2
- Molecular weight
- 663.4 g/mol
Research form
- Peptide type
- Research-grade reference material
- Research category
- Anti-Aging
- Appearance
- Per project specification
- Supplied form
- Per project
Reference identity: Nadide on NIH PubChem. Confirm order-specific identity and analytical results against the supplied batch documentation.
Available specifications
CelluPep supports catalog and bulk NAD+ inquiries. Final availability is confirmed after the requested quantity, purity and packaging requirements are reviewed.
- Purity options
- >99%
- Quantity
- 100mg × 10 vials · 500mg × 10 vials · 1000mg × 10 vials
- Packaging
- 100mg × 10 vials
- Labeling
- Standard, private-label and OEM requirements
- Minimum order
- Confirmed according to specification and packaging
- Lead time
- Confirmed with current batch or production availability
Quality documentation
Document availability is confirmed for the requested specification and production batch. Ask the sales team which analytical files are available before placing an order.
Batch-specific COAProduct identity, batch reference and available quality results are organized for document review.
HPLC analysisPurity information for the relevant batch
MS analysisIdentity information for the relevant batch
Manufacturing and supply process
Each inquiry is reviewed against the requested product specification, quantity, documentation and destination.
- Share requirementsSend the target quantity, purity, packaging and destination.
- Confirm specificationOur team reviews availability, documentation and lead time.
- Prepare supplyPackaging and labeling are matched to the confirmed order.
- Arrange shipmentShipping options are confirmed for the destination market.
Packaging, storage and shipping
Standard vial supply, custom labeling, OEM packaging and bulk quantities can be discussed with the CelluPep team.
Packaging
Sealed research vials with specification-dependent labeling and packing options.
Storage
Storage and handling conditions are confirmed in the project specification and batch documentation.
Shipping
Lead time and shipping arrangements depend on quantity, specification and destination.
NAD+ supply questions
What NAD+ specifications are available?
Availability depends on the requested quantity, purity and packaging format. Send your requirements for current specification confirmation.
Can I request a batch-specific COA?
Yes. Ask the sales team to confirm the documentation available for the relevant specification and batch.
Does CelluPep support bulk NAD+ inquiries?
Bulk requirements can be reviewed for qualified laboratory, biotechnology and distribution customers.
Is custom vial labeling available?
Custom labeling, private-label and OEM packaging requirements can be discussed during quotation.
What information is needed for a quotation?
Please provide the product name, target quantity, preferred specification, packaging requirements and shipping destination.
Is this product intended for human use?
No. This page describes material supplied for research use only. It is not offered for human consumption, diagnosis or therapeutic use.
Technical and supply resources
Page owner: CelluPep Product and Quality Team. Updated September 5, 2026.
